glp 1 agonist in ckd GLP-1 and the kidney: from physiology to pharmacology and outcomes diabetes image3.png
Description
Xiong H, Zheng C, Wang J, et al
Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of alzheimers disease
10.3389/fendo.2022.1033479 Front
Rising prevalence of diabetes and obesity, advancement in drug delivery technologies, and growing focus on preventive healthcare and personalized medicine are major key factors driving the market revenue growth of the GLP-1 Receptor Agonist market
Jr., et al
Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive
